Daniel Pink

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Topics

Prognostic Factors

Palliative Care

Ejection Fraction

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Bernd Kasper, Daniel Pink, Christian Rothermundt, Stephan Richter, Marinela Augustin, Attila Kollár, Annegret Kunitz, Wolfgang Eisterer, Verena Gaidzik, Thomas Brodowicz, Gerlinde Egerer, Peter Reichardt, Peter Hohenberger, Markus K Schuler
Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13). Cancers 16 (3) (2024)
Hanna Salm, Florian Doberschütz, Franziska Hallmann, Philipp Munzert, Johannes Rahm, Sarah Uhlig, Daniel Pink
How Do Quality of Life (QoL) and Symptom Burden Evolve in Inpatient Palliative Care (PC) Patients following One Week of Care in a Specialized Palliative Care Unit (PCU)? A Comparison of Two Groups, with One Receiving Specialized Outpatient Palliative Care Prior to Admission. Cancers 16 (8) (2024)
Maya Niethard, Carolin Knebel, Andreas Leithner, Per-Ulf Tunn, Janosch Schoon, Peter Reichardt, Athanasios Pogkas, Joanna Szkandera, Daniel Pink, Dimosthenis Andreou
What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity. Cancers 16 (9) (2024)
Hanna Salm, Florian Doberschütz, Franziska Hallmann, Philipp Munzert, Johannes Rahm, Sarah Uhlig, Daniel Pink
How Do Quality of Life (QoL) and Symptom Burden Evolve in Inpatient Palliative Care (PC) Patients following One Week of Care in a Specialized Palliative Care Unit (PCU)? A Comparison of Two Groups, with One Receiving Specialized Outpatient Palliative Care Prior to Admission. Cancers 16 (8) (2024)
Maya Niethard, Carolin Knebel, Andreas Leithner, Per-Ulf Tunn, Janosch Schoon, Peter Reichardt, Athanasios Pogkas, Joanna Szkandera, Daniel Pink, Dimosthenis Andreou
What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity. Cancers 16 (9) (2024)
Bernd Kasper, Daniel Pink, Christian Rothermundt, Stephan Richter, Marinela Augustin, Attila Kollár, Annegret Kunitz, Wolfgang Eisterer, Verena Gaidzik, Thomas Brodowicz, Gerlinde Egerer, Peter Reichardt, Peter Hohenberger, Markus K Schuler
Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13). Cancers 16 (3) (2024)
Viktor Gruenwald, Daniel Pink, Gerlinde Egerer, Enrico Schalk, Marinela Augustin, Christoph K W Deinzer, Viola Kob, Dietmar Reichert, Maxim Kebenko, Stephan Brandl, Dennis Hahn, Lars Hartwin Lindner, Mathias Hoiczyk, Uta Ringsdorf, Lars C Hanker, Dirk Hempel, Beatriz De Rivas, Tobias Wismann, Philipp Ivanyi
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial. Cancers 14 (21) (2022)
Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, Thomas Brodowicz, Bernd Kasper, Peter Reichardt, Stephan Richter, Lars Hartwin Lindner, Joanna Szkandera, Viktor Gruenwald, Maxim Kebenko, Marietta Kirchner, Peter Hohenberger
Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06). Cancers 13 (6) (2021)
Martin Eichler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Susanne Singer, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Vitali Heidt, Christine Hofbauer, Marius Fried, Verena I Gaidzik, Karl Verpoort, Marit Ahrens, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K Schuler, null The PROSa Study Group
The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa). Cancers 12 (12) (2020)